572 related articles for article (PubMed ID: 25885425)
21. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
[TBL] [Abstract][Full Text] [Related]
23. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
[TBL] [Abstract][Full Text] [Related]
24. Current treatment strategy of acute promyelocytic leukemia.
Mi J
Front Med; 2011 Dec; 5(4):341-7. PubMed ID: 22198746
[TBL] [Abstract][Full Text] [Related]
25. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
Liu P; Han ZC
Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
[TBL] [Abstract][Full Text] [Related]
26. [An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
Zhang X; Yang L; Qiao Z
Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):113-5. PubMed ID: 11798639
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.
Tallman M; Lo-Coco F; Barnes G; Kruse M; Wildner R; Martin M; Mueller U; Tang B
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):771-7. PubMed ID: 26361645
[TBL] [Abstract][Full Text] [Related]
28. Acute promyelocytic leukemia in childhood.
Gregory J; Feusner J
Curr Oncol Rep; 2009 Nov; 11(6):439-45. PubMed ID: 19840521
[TBL] [Abstract][Full Text] [Related]
29. All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
Ma Y; Liu L; Jin J; Lou Y
PLoS One; 2016; 11(7):e0158760. PubMed ID: 27391027
[TBL] [Abstract][Full Text] [Related]
30. The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
Jing Y; Waxman S
Curr Top Microbiol Immunol; 2007; 313():245-69. PubMed ID: 17217047
[TBL] [Abstract][Full Text] [Related]
31. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
[TBL] [Abstract][Full Text] [Related]
32. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
Korístek Z; Zák P
Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
[TBL] [Abstract][Full Text] [Related]
33. First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid.
Creutzig U; Dworzak MN; Bochennek K; Faber J; Flotho C; Graf N; Kontny U; Rossig C; Schmid I; von Stackelberg A; Mueller JE; von Neuhoff C; Reinhardt D; von Neuhoff N
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28111878
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
Huang H; Qin Y; Xu R; You X; Teng R; Yang L; Xu M; Liu H
Leuk Res; 2012 Jul; 36(7):841-5. PubMed ID: 22534100
[TBL] [Abstract][Full Text] [Related]
35. [Therapies for newly diagnosed acute promyelocytic leukemia].
Yokoyama Y
Rinsho Ketsueki; 2020; 61(9):1166-1173. PubMed ID: 33162512
[TBL] [Abstract][Full Text] [Related]
36. Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
Vassilakopoulos TP; Asimakopoulos JV; Plata E; Kelepesis G; Petevi K; Koutsi C; Papageorgiou L; Tsaftaridis P; Angelopoulou MK; Konstantopoulos K; Meletis J
Leuk Lymphoma; 2017 Jul; 58(7):1743-1746. PubMed ID: 27919176
[No Abstract] [Full Text] [Related]
37. Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis.
Langdon K; Cosentino S; Wawryk O
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2035. PubMed ID: 38507294
[TBL] [Abstract][Full Text] [Related]
38. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease.
Breccia M; Lo-Coco F
Expert Opin Pharmacother; 2012 May; 13(7):1031-43. PubMed ID: 22468778
[TBL] [Abstract][Full Text] [Related]
39. Differentiation syndrome in patients with acute promyelocytic leukemia.
Rogers JE; Yang D
J Oncol Pharm Pract; 2012 Mar; 18(1):109-14. PubMed ID: 21364078
[TBL] [Abstract][Full Text] [Related]
40. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
